Company profile
Real Brands, Inc.
OTC: RLBD · Healthcare · Drug Manufacturers - Specialty & Generic
PublicHQ North Providence, RICIK 0001084133Reports USD
#1073 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
——FH —DQ 17GM —SS 33
v0.1 · 25/100 weight · pillars only
↑ net margin, return on assets · ↓ workforce scale, disclosure history
Methodology →Revenue TTM
$80.7k
Rev growth YoY (TTM)
+204.2%
Net income (FY)
$1.3M
Employees
1
as of 2026-08-29
Market cap
$26.9k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$60.5k$60.5k2023
Net income$1.3M$1.3M2023
Operating income-$1.2M-$1.2M2023
Total assets$1.3M$1.3M2023
Liabilities$2.6M$2.6M2023
Equity-$1.3M-$1.3M2023
Revenue trend
FY2021 – FY2023 · USD
FY21
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Real Brands, Inc.’s revenue?
Real Brands, Inc. booked $60.5k in FY2023 revenue, growing 443% year over year — faster than 94% of Healthcare companies we track, at a 2203.9% net margin.
Peers · Healthcare
Kali, Inc.——Connect Biopharma Holdings Limited25DOxford Investments Holdings Inc.——Avalo Therapeutics, Inc.41DMicro Imaging Technology, Inc.——Therma Bright Inc.23DKey facts
CEOThomas Kidrin
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersNorth Providence, RI
ExchangeOTC: RLBD
Employees1
IPO date2000-11-22
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.